KAITLYN MARKS: Open Payments
NPI 1619661014 · ALTOONA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,856 in 102 payments from 12 companies in 2025. Trend: 2023 $449 · 2024 $1,423 · 2025 $1,856
Food & beverage: $1,771Education: $85
| Company | Payments | Amount |
|---|---|---|
| Ardelyx, Inc. | 25 | $541 |
| ABBVIE INC. | 30 | $438 |
| Janssen Biotech, Inc. | 11 | $281 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 18 | $216 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $127 |
| Ipsen Biopharmaceuticals, Inc | 4 | $67 |
| Regeneron Healthcare Solutions, Inc. | 3 | $65 |
| Madrigal Pharmaceuticals | 1 | $39 |
| Celltrion USA Inc. | 1 | $27 |
| GENZYME CORPORATION | 1 | $21 |
Products named: IBSRELA, TREMFYA, RINVOQ, XIFAXAN, CREON, DUPIXENT, LINZESS, ENTYVIO.
Industry payments across PA — which companies pay providers there.
